drugset / Trial / NCT00640367

Intra-arterial Versus Systemic Thrombolysis for Acute Ischemic Stroke

NCT00640367

Phase 3 Completed 350 enrolled Niguarda Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

SYNTHESIS is a pragmatic multicenter randomized controlled trial (RCT), open-label, with blinded follow-up aiming to determine whether loco-regional intra-arterial (IA) with recombinant tissue-plasminogen activator (rt-PA) and/or mechanical devices, as compared with systemic intravenous (I.V.) infusion of rt-PA within 3 hours of ischemic stroke, increases the proportion of independent survivors at 3 months.

Timeline

Start
2008-02
Primary completion
2009-02
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alteplase Protein / enzyme biologic 0.9 mg/kg Intravenous

Indications